On September 23-24, at the National Scientific Cardiosurgical Center, and on September 25-26, at the Hospital of the Medical Center of the Office of the President of the Republic of Kazakhstan, the world-renowned cardiologist Professor Serge Boveda from the French Clinique Pasteur, who is also the Secretary of the European Heart Rhythm Association (EHRA), held master classes on the application of new technology. This procedure is minimally invasive: a catheter is inserted through the femoral vein and directed to the heart, where electroporation is used to target only the pathological tissues. The entire process takes no more than an hour, and patients can return to normal life in a couple of days,” the professor said.
Kazakhstan was the first country in the CIS to introduce the latest technology for treating cardiac arrhythmias. UMC Heart Center specialists have successfully implemented Farapulse electropulse ablation, a cutting-edge technique for treating cardiac arrhythmias that is used in leading clinics around the world. The technology is highly safe and effective, and patients recover from the procedure in just 1-2 days.
Farapulse technology has been introduced in Kazakhstan for the first time among the CIS and Central Asian countries. It is used in patients with atrial fibrillation, a rapid and irregular contraction of the upper chambers of the heart.
“The technology allows for targeted treatment of arrhythmia zones without affecting healthy tissues, making the treatment as safe as possible for the patient,” said Omirbek Nuralinov, Head of the Department of Interventional Arrhythmology at the UMC Heart Center.
The introduction of this technology is particularly relevant, as cardiovascular diseases remain one of the leading causes of death worldwide.
“In Kazakhstan, about 1,000 patients need treatment for atrial fibrillation every year, and thanks to the government quota, they will be able to receive this high-tech care for free,” said Yuri Py, Chairman of the Board of UMC.
The workshops were held with the support of Boston Scientific and Dana Estrella.